SUPN · Nasdaq · CIK 0001356576

SUPERNUS PHARMACEUTICALS, INC.

SUPERNUS PHARMACEUTICALS, INC.’s most recent SEC filing in our snapshot is a Form 8-K filed on Oct 26, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $719.0M and net income of -$38.5M, according to its XBRL data on EDGAR. Its EDGAR record lists 49 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$719.0M
Net income, FY2025
-$38.5M
Form 4 filings on record, past 12 months
49

Company overview

Legal name (as filed)
SUPERNUS PHARMACEUTICALS, INC.
Ticker
SUPN
SEC Central Index Key (CIK)
0001356576
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
ROCKVILLE, MD
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1853 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from SUPERNUS PHARMACEUTICALS, INC.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$579.8MFY2021$667.2MFY2022$607.5MFY2023$661.8MFY2024$719.0MFY2025
Net income
$53.4MFY2021$60.7MFY2022$1.3MFY2023$73.9MFY2024-$38.5MFY2025
SUPN annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$579.8M$667.2M$607.5M$661.8M$719.0M
Net income$53.4M$60.7M$1.3M$73.9M-$38.5M
Diluted EPS$0.98$1.04$0.02$1.32-$0.68
Total assets$1.7B$1.7B$1.3B$1.4B$1.5B
Cash and equivalents$203.4M$93.1M$75.1M$69.3M$128.4M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

SUPN latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 2, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 26, 20268-KAgreement terminated· period Oct 26, 2026Document · Index
Apr 30, 2026DEF 14ADefinitive proxy statement· period Jun 18, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about SUPERNUS PHARMACEUTICALS, INC., by form type:

8-K ×124 ×10425 ×6DEFA14A ×510-Q ×2DEFM14A ×1SCHEDULE 13G/A ×1S-8 ×1SCHEDULE 13G ×1ARS ×1
SUPN recent filings
FiledFormWhat it isOriginal
Oct 26, 20268-KAgreement terminated· period Oct 26, 2026Document · Index
Oct 22, 20268-KOther events· period Oct 21, 2026Document · Index
Oct 19, 20268-KResults of operations· period Oct 19, 2026Document · Index
Oct 15, 20268-KShareholder vote results· period Oct 15, 2026Document · Index
Oct 6, 2026425425Document · Index
Oct 6, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Sep 11, 2026DEFM14ADEFM14ADocument · Index
Aug 14, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 12, 2026Document · Index
Aug 14, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 12, 2026Document · Index
Aug 14, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 12, 2026Document · Index
Aug 14, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 12, 2026Document · Index
Aug 14, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 12, 2026Document · Index
Aug 6, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 4, 2026425425Document · Index
Aug 3, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 3, 20268-KResults of operations· period Aug 3, 2026Document · Index
Aug 3, 2026425425Document · Index
Aug 3, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Aug 3, 2026425425Document · Index
Aug 3, 20268-KOther events· period Aug 3, 2026Document · Index
Aug 3, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Aug 3, 2026425425Document · Index
Aug 3, 20268-KOther events· period Aug 3, 2026Document · Index
Aug 3, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Aug 3, 2026425425Document · Index
Aug 3, 20268-KMaterial agreement; Director or officer change; Other events· period Aug 1, 2026Document · Index
Jul 31, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 29, 2026Document · Index
Jul 31, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 29, 2026Document · Index
Jul 31, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 29, 2026Document · Index
Jul 31, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 29, 2026Document · Index
Jul 31, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 29, 2026Document · Index
Jul 22, 20268-KResults of operations· period Jul 22, 2026Document · Index
Jun 22, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Jun 18, 20268-KShareholder vote results· period Jun 18, 2026Document · Index
May 20, 20268-KNew financial obligation· period May 17, 2026Document · Index
May 5, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 5, 20268-KResults of operations· period May 5, 2026Document · Index
Apr 30, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Apr 30, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 30, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index

Insider filing activity

49 Form 4 filings appear in SUPERNUS PHARMACEUTICALS, INC.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Maryland

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001356576 and XBRL company facts. SUPERNUS PHARMACEUTICALS, INC. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.